Thursday, 5 November 2026European Markets

ADC SIIC Stock Jumps By 29% In The Last 10 Sessions

Loading stream...

adc siic, a real estate investment firm, experienced a significant rise in its stock performance recently. over a span of 10 sessions, its shares escalated by 29.63% to a value of eur0.07. this came as a recovery from successive losses and was accompanied by a subsequent rise in the cac 40 index, which saw an increase of 1.02% to stand at eur7,343.96.

stock performance overview

the shares of adc siic have exhibited a swing in their performance, where they have overrun their 52-week low of eur0.05 and yet have not hit their 52-week high of eur0.08. this swing in performance mirrors the financial health of the company in recent years.

financial performance

adc siic demonstrated a substantial year-over-year quarterly revenue growth. it marked an increase of 351.3%, reaching a volume of 1.01m for the trailing twelve months. despite such an impressive revenue upswing, the company unfortunately couldn't utilize it towards yielding profits, resulting in negative earnings per share (eps) of eur-0.01 and an equity return rate of -1.87%.

trading volume and investor activity

adc siic, even with its recent surge in stock price, witnessed a trading volume of only 6,000 which is much below its average volume of 9,222. this suggests that investor activity is rather inactive, as not many are engaging in trading this stock despite its shift in momentum.

stock's future prospects

adc siic's stock value currently leads beyond its 50-day and 200-day moving averages of eur0.07. nevertheless, its future prospects are shadowed by negative eps, a sluggish trading volume, and an absence of profitability. as a result, prospective investors must practice extreme caution before considering this stock because of the inherent volatility and financial risk associated with it.

more news about adc siic (aldv.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,549 source documents archived
Query this data → isubstrate.com